TY - JOUR
T1 - Rapid improvement in a terminal case of hairy cell leukemia treated with a new human recombinant interferon, IFN-α-C
AU - Aderka, D.
AU - Levo, Y.
AU - Rahmani, R.
AU - Mory, Y.
AU - Vaks, B.
AU - Horowitz, O.
AU - Doerner, T.
AU - Shoham, J.
AU - Wallach, D.
AU - Revel, M.
PY - 1985
Y1 - 1985
N2 - A new type of human interferon (IFN), IFN-α-C, produced in Escherichia coli and purified on monoclonal antibodies, was given at a dose of 3 x 106 u (3 μg)/day to a terminally ill unsplenectomized patient with hairy cell leukemia, who had had severe recurrent infections and pancytopenia. There was marked reduction in the size of the spleen after 2 weeks, and platelet counts returned to normal after 1 month of treatment. The IFN treatment also raised the granulocyte counts and hemoglobin levels, improved the normal repopulation of the bone marrow, and restored resistance to infections. IFN-α-C was well tolerated, without serious side effects, and treatment has been continued for 10 months.
AB - A new type of human interferon (IFN), IFN-α-C, produced in Escherichia coli and purified on monoclonal antibodies, was given at a dose of 3 x 106 u (3 μg)/day to a terminally ill unsplenectomized patient with hairy cell leukemia, who had had severe recurrent infections and pancytopenia. There was marked reduction in the size of the spleen after 2 weeks, and platelet counts returned to normal after 1 month of treatment. The IFN treatment also raised the granulocyte counts and hemoglobin levels, improved the normal repopulation of the bone marrow, and restored resistance to infections. IFN-α-C was well tolerated, without serious side effects, and treatment has been continued for 10 months.
UR - http://www.scopus.com/inward/record.url?scp=0022403268&partnerID=8YFLogxK
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 4093298
AN - SCOPUS:0022403268
SN - 1565-1088
VL - 21
SP - 977
EP - 981
JO - Israel Medical Association Journal
JF - Israel Medical Association Journal
IS - 12
ER -